• Home
• About us
• Products
• Partnering
• Investors
• Media
• Contact us

• Print page
• Bookmark page
• Email us

Move to Official List

Not for release or distribution or publication in whole or part in or into the United States, Canada, Japan or Australia

Vectura Group plc - Proposed move from AIM to the Official List and notice of intended cancellation of AIM listing

4 June 2007, Chippenham, UK. Vectura Group plc ("the Company") today announces that, as referred to in its preliminary results announcement on 23 May 2007, the Company intends to apply for admission of its ordinary shares to the Official List of the UK listing Authority ("Official List") and to trading on the London Stock Exchange's market for listed securities.

Pursuant to Rule 41 of the AIM Rules, the Company hereby gives notice of the intended cancellation of trading of its ordinary shares on the AIM market of the London Stock Exchange.

It is expected that the Company's ordinary shares will be simultaneously cancelled on AIM and admitted to the Official List and to trading on the London Stock Exchange in July, subject to the receipt of necessary approvals from the relevant regulatory authorities for each exchange.

The Directors believe that the Company has now reached a size at which it will benefit from the increased international profile of the Official List. The move will broaden Vectura's potential domestic and international investor base and should increase both liquidity of the shares and the profile of the Company.

- Ends -

Enquiries:

About Vectura
Vectura is a pulmonary drug development company focused principally on the development of a range of inhaled therapies for the treatment of respiratory and neurological diseases. The Company targets opportunities where optimised delivery via the lungs can provide significant benefits, such as a rapid onset of action, improved efficacy and improved tolerability compared with current therapies.

Vectura has eight marketed products and a portfolio of drugs in clinical and pre-clinical development, some of which have been licensed to major pharmaceutical companies. The Company also seeks to develop certain programmes further through development to optimise value at a later licensing stage. Vectura also offers its formulation and inhalation capabilities to other pharmaceutical companies on a licensing basis where this complements Vectura's business strategy.

Vectura has development collaborations with a broad range of pharmaceutical companies including Boehringer Ingelheim, Novartis, GSK and Chiesi. The acquisition of Innovata in January 2007 brought established alliances with a number of additional companies, such as Baxter, Merck KGaA, UCB and Otsuka as well providing revenue streams, complementary products and critical mass.

For further information, please visit Vectura's website at www.vectura.com

This press release contains "forward-looking statements," including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including adverse results in clinical development programs; failure to obtain patent protection for discoveries; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.